News

Therini Bio Announces Positive Phase 1a Trial Results Evaluating THN391 for Neurodegenerative Diseases

- Novel approach to treat neurodegenerative diseases by targeting fibrin-driven neuroinflammation was well-tolerated among healthy volunteers, with a clean hematological…

8 months ago

Therini Bio Announces Positive Phase 1a Trial Results Evaluating THN391 for Neurodegenerative Diseases

- Novel approach to treat neurodegenerative diseases by targeting fibrin-driven neuroinflammation was well-tolerated among healthy volunteers, with a clean hematological…

8 months ago

Instinct Science Sponsors NOMV’s Race Around the World to Support Veterinary Mental Health

PHILADELPHIA, April 29, 2025 (GLOBE NEWSWIRE) -- Not One More Vet (NOMV), the leading nonprofit focused on mental health in…

8 months ago

Instinct Science Sponsors NOMV’s Race Around the World to Support Veterinary Mental Health

PHILADELPHIA, April 29, 2025 (GLOBE NEWSWIRE) -- Not One More Vet (NOMV), the leading nonprofit focused on mental health in…

8 months ago

Acentra Health Awarded $27.5 Million Contract from California Medicaid to Continue Providing Preadmission Screening and Resident Review (PASRR) Services

Award follows new contracts in Kansas and Washington and expands the company’s PASRR services for long-term care assessments to eight…

8 months ago

Acentra Health Awarded $27.5 Million Contract from California Medicaid to Continue Providing Preadmission Screening and Resident Review (PASRR) Services

Award follows new contracts in Kansas and Washington and expands the company’s PASRR services for long-term care assessments to eight…

8 months ago

Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting

Updated clinical and preclinical data showcase iPSC-derived off-the-shelf CAR T-cell therapy products for conditioning chemotherapy-free treatment across autoimmune and cancer…

8 months ago

Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting

Updated clinical and preclinical data showcase iPSC-derived off-the-shelf CAR T-cell therapy products for conditioning chemotherapy-free treatment across autoimmune and cancer…

8 months ago

FibroBiologics Presents at the ThymUS 2025 Meeting

HOUSTON, April 29, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued…

8 months ago

FibroBiologics Presents at the ThymUS 2025 Meeting

HOUSTON, April 29, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued…

8 months ago